$1.760
+0.347 (+19.73%)At close
NCNA News
NCNA Events
NuCana Appoints Ian Webster as CFO
NuCana announced the appointment of Ian Webster as CFO, effective immediately. Ian has served as interim CFO since June 2025 and was previously director of finance since joining NuCana in 2019.
NuCana Appoints Theresa Bruce as COO Effective January 1, 2026
NuCana announced the appointment of Theresa Bruce as Chief Operating Officer, COO, effective January 1, 2026. Bruce previously served as Chief Operating Officer at Nexus Oncology
NuCana Presents NUC-7738 Clinical Data at ESMO Congress
NuCana presented the latest clinical data at the annual European Society for Medical Oncology, ESMO, Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 inhibitor-resistant metastatic melanoma treated with NUC-7738 in combination with pembrolizumab continue to demonstrate clinical activity and a favorable safety profile. All patients had progressive disease prior to starting treatment. Clinical activity includes two partial responses and seven cases of stable disease, notably including one ongoing stable disease converting to a complete metabolic response with no detectable active disease. These results further reinforce the initial findings presented at the ESMO Congress 2024.
NuCana Presents NUC-7738 Clinical Data at ESMO Congress
NuCana presented the latest clinical data at the annual European Society for Medical Oncology, ESMO, Immuno-Oncology Congress, December 10-12, 2025, in London. The data from patients with PD-1 inhibitor-resistant metastatic melanoma treated with NUC-7738 in combination with pembrolizumab continue to demonstrate clinical activity and a favorable safety profile. All patients had progressive disease prior to starting treatment. Clinical activity includes two partial responses and seven cases of stable disease, notably including one ongoing stable disease converting to a complete metabolic response with no detectable active disease. These results further reinforce the initial findings presented at the ESMO Congress 2024. As of the most recent analysis, nine patients have been treated in the Expansion Cohort, which is part of the planned enrollment of up to 28 additional patients. Combined with the 12 patients previously treated in the Dose Confirmation Cohort, this will provide a total combination dataset comprising up to 40 patients.
NuCana Secures Composition-of-Matter Patent for NUC-7738 in China
NuCana announced that the China National Intellectual Property Administration, CNIPA, has granted an important patent covering the composition of matter for NUC-7738. This patent is expected to serve as a key component of the patent protection for NUC-7738, which currently consists of over 85 issued patents worldwide. The composition of matter patent covers the chemical structure of NUC-7738, NuCana's novel anti-cancer agent currently being evaluated in a Phase 1/2 clinical study in combination with pembrolizumab for patients with PD-1 inhibitor refractory or resistant melanoma. Securing this patent represents an important milestone for NuCana, strengthening its long-term global intellectual property strategy, while supporting potential opportunities to address unmet needs for innovative cancer therapies in China.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。